TABLE 4.
Guideline recommendations on primary thromboprophylaxis in ambulatory patients with cancer treated with immune checkpoint inhibitors
| Guideline | Recommends primary thromboprophylaxis during checkpoint inhibitor treatment? | Which Khorana score threshold? | Recommended treatment duration |
|---|---|---|---|
| NCCN 2022 39 | Yes, any systemic treatment | Khorana score ≥2 | Six months (“longer if risk persists”) |
| ASH 2021 40 | Yes, any systemic treatment | Both intermediate and high‐risk patients according to Khorana score (i.e., score ≥1) | Not specified |
| ASCO 2020 41 | No, only chemotherapy | Khorana score ≥2 | “Discuss with patient” |
| ITAC 2022 42 | Yes, any systemic treatment | Khorana score ≥2 | Not specified |
| ISTH 2019 43 | No, only chemotherapy | Khorana score ≥2 | Six months |
Abbreviations: ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; ISTH, International Society on Thrombosis and Haemostasis; ITAC, International Initiative on Thrombosis and Cancer; NCCN, National Comprehensive Cancer Network.